Hims CEO Addresses Scrutiny of Compounded GLP-1s in Earnings Call
Hims & Hers CEO Andrew Dudum addressed increasing scrutiny of compounded GLP-1s, discussing the impact on the company's financials and future plans.
Search
Search exact matches first, then pivot into a structured research workspace when direct coverage is thin.
Article matches
Hims & Hers CEO Andrew Dudum addressed increasing scrutiny of compounded GLP-1s, discussing the impact on the company's financials and future plans.
Tesla is reinventing itself as a technology company focusing on autonomy. The rise of affordable oral medications like RO's GLP-1 is transforming the pharmaceutical industry.
A review of the UK's social care system and advancements in endometriosis diagnosis
Pharmaceutical lobby leader steps down, Medicare funding sparks debate, and biotech VCs face disruption
FDA targets telehealth marketing, GPs open up about mental health concerns, and the biotech industry marks 50 years
Experts weigh in on GLP-1, Gen Z, AI, and the national debt
Advances in autophagy, GLP-1 therapies, sleep deprivation, and design history
Discover the latest news on Apple's potential new iPhone camera feature, Kim Kardashian's new energy drink venture, and research on GLP-1 medications, as well as insights on career strategies and investing.
Businesses are adapting to the rise in popularity of GLP-1 drugs for weight loss. In reality TV, it's not just what contestants say or do that influences their fellow players - it's also how they dress.